Cushing’s syndrome is commonly complicated with an impairment of glucose metabolism, which is often clinically manifested as diabetes mellitus. The development of diabetes mellitus in Cushing’s syndrome is both a direct and indirect consequence of glucocorticoid excess. Indeed, glucocorticoid excess induces a stimulation of gluconeogenesis in the liver as well as an inhibition of insulin sensitivity both in the liver and in the skeletal muscles, which represent the most important sites responsible for glucose metabolism. In particular, glucocorticoid excess stimulates the expression of several key enzymes involved in the process of gluconeogenesis, with a consequent increase of glucose production, and induces an impairment of insulin sensitivity either directly by interfering with the insulin receptor signaling pathway or indirectly, through the stimulation of lipolysis and proteolysis and the consequent increase of fatty acids and amino acids, which contribute to the development of insulin resistance. Moreover, the peculiar distribution of adipose tissue throughout the body, with the predominance of visceral adipose tissue, significantly contributes to the worsening of insulin resistance and the development of a metabolic syndrome, which participates in the occurrence and maintenance of the impairment of glucose tolerance. Finally, glucocorticoid excess is able to impair insulin secretion as well as act at the level of the pancreatic beta cells, where it inhibits different steps of the insulin secretion process. This phenomenon is probably responsible for the passage from an impairment of glucose tolerance to an overt diabetes mellitus in susceptible patients with Cushing’s syndrome.

1.
Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A: Cushing’s syndrome. Endocrinol Metab Clin North Am 2008;37:135–149.
2.
Resmini E, Minuto F, Colao A, Ferone D: Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009;46:85–95.
3.
van Raalte DH, Ouwens DM, Diamant M: Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81–93.
4.
McMahon M, Gerich J, Rizza R: Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988;4:17–30.
5.
Andrews RC, Walker BR: Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96:513–523.
6.
Vegiopoulos A, Herzig S: Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007;275:43–61.
7.
Rooney DP, Neely RD, Cullen C, et al: The effect of cortisol on glucose/glucose-6-phosphate cycle activity in insulin action. J Clin Endocrinol Metab 1993;77:1180–1183.
8.
Vander Kooi BT, Onuma H, Oeser JK, et al: The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol 2005;19:3001–3022.
9.
Kraus-Friedman N: Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 1984;64:170–259.
10.
Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L: Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 2000;19:29–34.
11.
Rizza RA, Mandarino LJ, Gerich JE: Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982;54:131–138.
12.
Saad MJ, Folli F, Kahn JA, Kahn CR: Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 1993;92:2065–2072.
13.
Weinstein SP, Wilson CM, Pritsker A, Cushman SW: Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998;47:3–6.
14.
Ruzzin J, Wagman AS, Jensen J: Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005;48:2119–2130.
15.
Seckl JR, Morton NM, Chapman KE, Walker BR: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004;59:359–393.
16.
Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548–2556.
17.
Kahn SE: The relative contributions of insulin resistance and beta cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3–19.
18.
Gremlich S, Roduit R, Thorens B: Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 1997;272:3216–3222.
19.
Borboni P, Porzio O, Magnaterra R, et al: Quantitative analysis of pancreatic glucokinase gene expression in cultured beta cells by competitive polymerase chain reaction. Mol Clin Endocrinol 1996;117:175–181.
20.
Ullrich S, Berchtold S, Ranta F, et al: Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005;54:1090–1099.
21.
van Raalte D, Nofrate V, Bunck M, Van Iersel T, Elassaiss Schaap J, Nãssander U, Heine R, Mari A, Dokter W, Diamant M: Acute and two-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 2010;162:729–735.
22.
Matsumoto K, Yamasaki H, Akazawa S, et al: High dose but not low dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta cells in normal men. J Clin Endocrinol Metab 1996;81:2621–2626.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.